Cargando…

Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study

Breast cancer patients historically benefitted from population-based genetic research performed in South Africa, which led to the development of founder-based BRCA1/2 diagnostic tests. With the advent of next-generation sequencing (NGS) technologies, the clinical utility of limited, targeted genetic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oosthuizen, Jaco, Kotze, Maritha J., Van Der Merwe, Nicole, Myburgh, Ettienne J., Bester, Phillip, van der Merwe, Nerina C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908826/ https://www.ncbi.nlm.nih.gov/pubmed/33643918 http://dx.doi.org/10.3389/fonc.2020.619469

Ejemplares similares

The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer
por: van der Merwe, Nerina C., et al.
Publicado: (2020)

Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience
por: Van der Merwe, Nerina C., et al.
Publicado: (2022)

Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint
por: Myburgh, Ettienne J., et al.
Publicado: (2016)

Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector
por: van der Merwe, Nerina C., et al.
Publicado: (2022)

Pioneering Informed Consent for Return of Research Results to Breast Cancer Patients Facing Barriers to Implementation of Genomic Medicine: The Kenyan BRCA1/2 Testing Experience Using Whole Exome Sequencing
por: Torrorey-Sawe, Rispah, et al.
Publicado: (2020)

Pioneering BRCA1/2 Point-Of-Care Testing for Integration of Germline and Tumor Genetics in Breast Cancer Risk Management: A Vision for the Future of Translational Pharmacogenomics
por: Mampunye, Lwando, et al.
Publicado: (2021)

BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study
por: Kowalik, Artur, et al.
Publicado: (2018)

A South African Indian population group dataset for breast cancer and BRCA1/2 variants
por: Combrink, H.M.V.E., et al.
Publicado: (2022)

Identification of a founder BRCA2 mutation in Sardinia
por: Pisano, M, et al.
Publicado: (2000)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application
por: van der Merwe, Nicole, et al.
Publicado: (2012)

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

Founder BRCA1 mutations in Nepalese population
por: Mehta, Anurag, et al.
Publicado: (2022)

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls
por: Behl, Supriya, et al.
Publicado: (2020)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
por: Solano, Angela R., et al.
Publicado: (2018)

BRCA Genetic Screening in Middle Eastern and North African: Mutational Spectrum and Founder BRCA1 Mutation (c.798_799delTT) in North African
por: Laraqui, Abdelilah, et al.
Publicado: (2015)

Evidence of a founder BRCA1 mutation in Scotland
por: Liede, A, et al.
Publicado: (2000)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile
por: Alvarez, Carolina, et al.
Publicado: (2017)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

Fat Mass and Obesity-Associated (FTO) Gene Polymorphisms Are Associated with Physical Activity, Food Intake, Eating Behaviors, Psychological Health, and Modeled Change in Body Mass Index in Overweight/Obese Caucasian Adults
por: Harbron, Janetta, et al.
Publicado: (2014)

The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population
por: Luo, Yu, et al.
Publicado: (2022)

The Icelandic founder mutation BRCA2 999del5: analysis of expression
por: Mikaelsdottir, Evgenia K, et al.
Publicado: (2004)

The complete mitochondrial genome of the South African snoek Thyrsites atun (Euphrasén, 1791) (Perciformes, Gempylidae)
por: Mthethwa, Siphesihle, et al.
Publicado: (2023)

Mutation Analysis of the BRCA1 and BRCA2 Genes in the Belgian Patient Population and Identification of a Belgian Founder Mutation BRCA1 IVS5+3A>G
por: Claes, Kathleen, et al.
Publicado: (1999)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

A Founder Mutation of the BRCA1-Gene in Western Sweden
por: Einbeigi, Zakaria, et al.
Publicado: (1999)

Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank
por: Abul-Husn, Noura S., et al.
Publicado: (2019)

Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening
por: Park, Joonhong, et al.
Publicado: (2016)

HIF-1α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers
por: van der Groep, Petra, et al.
Publicado: (2013)

Characterization of an Italian Founder Mutation in the RING-Finger Domain of BRCA1
por: Caleca, Laura, et al.
Publicado: (2014)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

BRCA1 and BRCA2 screening of nine Chilean founder mutations through allelic-discrimination and real-time PCR in breast/ovarian cancer patients
por: Alvarez, Carolina, et al.
Publicado: (2022)

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
por: Kuusisto, Kirsi M, et al.
Publicado: (2011)

Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families
por: Oros, Kathleen K, et al.
Publicado: (2006)

Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
por: Hamel, Nancy, et al.
Publicado: (2003)

Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing
por: Hirotsu, Yosuke, et al.
Publicado: (2015)

Building the What Comes Next Cohort for BRCA1 and BRCA2 testing: a descriptive analysis
por: Dossa, Fahima, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2pnrnlojc6nstb35i7jm6aca71